



## Mechanisms of Anticancer Drugs Resistance: An Overview

M. R. Chorawala<sup>1\*</sup>, P. M. Oza<sup>2</sup>, G. B. Shah<sup>1</sup>

<sup>1</sup>Department of Pharmacology, K. B. Institute of Pharmaceutical Education & Research, Gandhinagar-382023, Gujarat, India

<sup>2</sup>Department of Pharmaceutical Chemistry, K. B. Institute of Pharmaceutical Education & Research, Gandhinagar-382023, Gujarat, India

---

### ABSTRACT

The management of cancer involves surgery, radiotherapy and chemotherapy. Development of chemoresistance is a persistent problem during the chemotherapy treatment. Cytotoxic drugs that selectively, but not exclusively, target actively proliferating cells include such diverse groups as DNA-alkylating agents, anti-metabolites, intercalating agents and mitotic inhibitors. Resistance constitutes a lack of response to drug-induced tumour growth inhibition; it may be inherent in a subpopulation of heterogeneous cancer cells or be acquired as a cellular response to drug exposure. Principle mechanisms may include altered membrane transport involving the p-glycoprotein product of the multidrug resistance (MDR) gene as well as other associated proteins, altered target enzyme, decreased drug activation, increased drug degradation due to altered expression of drug metabolising enzymes, drug inactivation due to conjugation with increased glutathione, subcellular redistribution, drug interaction, enhanced DNA repair and failure to apoptosis as a result of mutated cell cycle proteins such as p53. Attempts to overcome resistance involves the use of combination drug therapy using different classes of drugs with minimally overlapping toxicities to allow maximal dosages, necessary for bone marrow recovery. Adjuvant therapy with p-glycoprotein inhibitors and in specific instances, the use of growth factor and protein kinase C inhibitors are newer experimental approaches that may also prove effective in delaying onset of resistance. Gene knockout using antisense molecules may be effective way of blocking drug resistance.

**Keywords:** Cancer, Chemotherapy, Drug resistance, Multidrug resistance protein, P-Glycoprotein.

---

### INTRODUCTION

Therapeutic procedures for cancer patients still remain largely empirical and vary between centers. Treatment depends upon a variety of individual factors, which may include the specific pathological and molecular characteristics of the cancer, its location, extent of disease and the health status of the patient. The ultimate objective is to destroy all the cancer cells whilst inflicting minimal damage on the normal tissue. This can be achieved in a number of ways, either directly or indirectly by depriving the cancer cells of signals needed for cellular proliferation or by stimulating an immune response.

There are several different types of treatment, which may be used alone or in combination, either simultaneously or sequentially: surgery, radiotherapy and drugs. Surgery is most frequently the first line of therapy, and for 'early' cancers, it may be curative. Radiotherapy is most often used

in a localised setting and in conjunction with surgical procedures. The use of drugs involves chemotherapy (CTX), which employs a wide group of drugs that have cytotoxic effects which preferentially, but not exclusively, target the rapidly dividing cancer cells. Endocrine therapy is a more specific form of treatment, used for example for breast cancer. It is aimed at preventing cancer cell proliferation by antagonising the estrogen-stimulated intracellular signals which control growth in cells over expressing the oestrogen receptor. This may be effective in 60–70% of breast cancer patients. Antibodies against specific proteins that are over expressed in cancer cells may be used to preferentially target those cells. Toxin molecules linked to the antibodies would be endocytosed into the cells and destroy them, such as Herceptin, which targets the erbB2/HER2/neu receptor.<sup>[1-2]</sup> Targeted therapies have been employed exploiting the over expression in many cancer cells of proteins such as the folate receptor.<sup>[3-4]</sup> Metabolic inhibitors are being investigated, which target specific proteins and pathways involved in cell growth that operate preferentially in cancer cells. Many of these are associated with cell cycle regulation. Biological response modifiers are a class of compounds, which may be modulated to elicit an immune response against cancer cells.

---

\*Corresponding author: Mr. Mehul R. Chorawala, Department of Pharmacology, K. B. Institute of Pharmaceutical Education & Research, Sector - 23, Near Gh-6 circle, Kadi pharmacy campus, Gandhinagar-382023, Gujarat, India; E-mail: [mehulchorawala@gmail.com](mailto:mehulchorawala@gmail.com)

Vaccines may offer an ideal solution, but so far the lack of tumour specific proteins has hampered this approach. Provenge® (Sipuleucel-T) is a vaccine recently approved by USFDA for metastatic castrate resistant prostate cancer patients and androgen independent prostate cancer. [5] Human Papilloma Virus (HPV) is DNA virus that infect the basal epithelial cells, which leads to cervical cancer as well as it is also associated with head and neck cancer. Recently a quadrivalent HPV vaccine has been approved for prophylactic against cervical cancer. [6] The advantage of HPV vaccine is non-infectious because it is prepared from empty protein cells by recombinant technology that does not contain any live biological product or DNA. Of these, chemotherapy and endocrine therapy are currently in use. Others are experimental or hopeful approaches for the future. This review describes the mechanisms of drug resistance in cancer chemotherapy.

### CHEMOTHERAPY

Although adjuvant CTX is frequently used for primary tumors, its main use is to control overt disseminated disease. The excessively active growth-signaling pathways in cancer cells makes them susceptible to a wide range of drugs which target growth-signaling molecules and/or processes involved in cellular replication and expression (Fig. 1). However, as these processes also drive normal cells, the effect is preferential and not exclusive, which results in the unwanted side-effects seen with these agents. Cells which are normally actively dividing, in particular the bone marrow constituents and those of the intestinal lining, are particularly susceptible. Disregulated cell cycle events, due to mutations in cancer cells, do sometimes offer opportunities to target those cells without affecting normal cells.

The relatively wide spectrum of activity of cytotoxic drugs makes them a rather harsh and non-specific form of treatment that can only be tolerated for short periods. Indeed the effects of the treatment may sometimes cause more distress than the disease. These side-effects include dry flaky skin, loss of hair, nausea and vomiting, changes in taste and appetite, blood clotting problems, fatigue, depressed immune system and possible sterility.




Fig. 1: Sites of action of cytotoxic agents.

Most side-effects subside after the treatment is over, but some-times there is permanent damage to the kidneys, heart,

lungs or reproductive system. In general, however, benefits outweigh the disadvantages, and CTX is the commonest form of cancer therapy. This is less a reflection of its effectiveness than the lack of a better alternative. The other chemical therapies in the list constitute some of these alternatives, but at present they play a subsidiary role in the armory of the oncologist. Many of the CTX drugs that are employed are naturally occurring compounds extracted from plants, while others are synthetic. They can be divided into three major groups on the basis of their mode and site of action (Fig. 1): anti-metabolites, genotoxic agents and mitotic spindle inhibitors (Table 1).

### FAILURE OF CHEMOTHERAPY

In some cases, tumors may be refractory to treatment with some types of cytotoxic drugs. In many, if not most instances, patients who initially respond to CTX invariably show a loss of response later on, resulting in tumor re-growth. There are two probable causes for this: (a) the tumor cells may be inherently resistant possibly due to some genetic characteristic or (b) they may acquire resistance following exposure to the drug. In a typical scenario, 1 in  $10^6$ - $10^7$  cancer cells in a tumor is likely to have inherent resistance against a particular drug. A clinically detectable tumor has in the region of  $10^9$  cells and it might therefore be expected to contain 10–1,000 drug resistant cells, which have the potential to repopulate the tumor despite destruction of the sensitive cells. Considering this, the probability of cure or containment is directly related to tumor size at onset of treatment. Aggressive CTX may often cure certain cancers, particularly childhood leukaemias, Hodgkin's disease or testicular cancers, because the few surviving drug-resistant cells may become susceptible to the immune system. Irrespective of how resistance to CTX arises, it poses a serious impediment to the successful elimination of the entire tumor mass. Drug resistance has been described as the single most common reason for discontinuation of a drug. [8]

### POTENTIAL MECHANISMS OF RESISTANCE

Various hypotheses, some with more supporting experimental evidence than others, have been proposed to account for the phenomenon of drug resistance. Ironically, some of the mechanisms that could be utilized by cancer cells to resist cytotoxic drugs are probably evolved in normal cells as a defense mechanism against environmental carcinogens. The hypothesis include altered transport of the drug across the plasma membrane, genetic responses, enhanced DNA repair, alteration in target molecules, access to target cells, metabolic effects and growth factors.

#### Altered Membrane Transport

Probably one of the most significant forms of resistance against the variety of currently used anti-neoplastic agents is by the action of a group of membrane proteins which extrude cytotoxic molecules, keeping intracellular drug concentration below a cell-killing threshold. These ATP-dependent multidrug transporters belong to the ubiquitous superfamily of ATP-binding cassette (ABC) proteins, which have also been implicated in the resistance to infectious diseases such as AIDS and malaria. These proteins modulate absorption, distribution and excretion of many pharmacological compounds. There may be as many as 48 genes encoding ABC transporters. The ABC proteins have been grouped into 7 subclasses ranging from ABCA to ABCG [9] based upon genomic organization, order of domains and sequence homology.

**Table 1: Various types of anti-cancer agents with their mechanisms and clinical uses.** <sup>[7]</sup>

CLASS	SUBCLASS WITH EXAMPLE	MECHANISM OF ACTION	CLINICAL USES
ANTIMETABOLITES	<b>FOLATE ANTAGONISTS:</b> Methotrexate	Inhibits the dihydrofolate reductase and thus affect nucleoside metabolism.	Acute Lymphoblastic Leukaemia (ALL), Choriocarcinoma, Cancer of breast-neck-head-lungs-cervical.
	<b>PYRIMIDINE ANTAGONISTS:</b> 5-Flourouracil Cytarabine Gemcitabine Capecitabine	Block pyrimidine nucleotide formation by incorporation into newly synthesized DNA.	Basal cell skin cancer, GIT adenocarcinoma, Cancers of breast-colon-stomach-rectum-pancreas, Cancer of prostate and bladder.
	<b>PURINE ANTAGONISTS:</b> 6-Mercaptopurine 6-Thioguanine	Act as fraud substrate for biochemical reactions and inhibit the synthetic steps during S-phase of replication.	Acute and Chronic myelogenous leukaemia, Acute lymphocytic leukaemia, Acute myelomonocytic leukaemia.
GENOTOXIC AGENTS (They bind to DNA and directly/indirectly affect the replication which induces the apoptosis.)	<b>ALKYLATING AGENTS:</b> Cisplatin Cyclophosphamide Melphalan Temazolomide Carmustine Ifosfamide Streptozotocin	Introduce alkyl groups into DNA and create cross linking between two DNA strands and inhibit protein synthesis.	Brain tumor, Testicular cancer, Head and Neck cancer, Hodgkin's disease, Pancreas carcinoma, Ovarian and bladder cancer.
	<b>INTERCALATING AGENTS:</b> Epirubicin Doxorubicin Dactinomycin	Drugs bind to DNA through intercalation between specific base pair thus block the DNA synthesis.	Breast cancer, Acute leukaemia, Endometrial cancer, Thyroid cancer, Wilm's tumor, Ewing's sarcoma, Rhabdomyelo sarcoma, Neuroblastoma.
	<b>ENZYME INHIBITORS:</b> Etoposide Topotecan Irinotecan	<b>Etoposide:</b> Inhibits topoisomerase II thus prevent resealing of DNA which leads to cell death. <b>Topotecan/Irinotecan:</b> Inhibits topoisomerase I which allows single strands break in DNA but not affect resealing.	Small cell lung cancer, Kaposi's sarcoma, Breast cancer. Cancer of ovary, lungs, colon and small cell lung cancer.
MITOTIC SPINDLE INHIBITORS	<b>VINCA ALKALOIDS:</b> Vincristine Vinblastine	Arrest the cell division in metaphase by binding to tubulin.	<b>Vincristine:</b> Acute Lymphocytic Leukaemia (ALL), Wilms tumor, Rhabdomyelo sarcoma, Breast-cervical-ovarian cancer. <b>Vinblastine:</b> Testicular carcinoma, Hodgkin's disease, Kaposi's sarcoma, cancer of breast-lungs-bladder.
	<b>TAXANES DERIVATIVES:</b> Paclitaxel Docetaxel	Stabilise polymerization of tubulins and inhibit the disassembly of microtubules.	Cancer of breast, ovary, lungs, head and neck.
	<b>PROTEIN TYROSINE KINASE INHIBITORS:</b> Imatinib	By inhibiting this enzyme, inhibit proliferation of myeloid cell.	Chronic myeloid leukaemia (CML), GIT stromal cell tumor.
NEWER AGENTS	<b>EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS:</b> Gefitinib Erlotinib	Activation of EGFR induces dimerisation and intracellular activation of protein tyrosine kinase (same as above).	Metastatic non-small cell lung cancer, solid tumors.
	<b>PROTEASOME INHIBITORS:</b> Bortezomib	Prevents degradation of intracellular protein leading to activation of signaling cascade, cell cycle arrest and apoptosis.	Refractory and relapsed multiple myeloma.
	<b>MONOCLONAL ANTIBODIES:</b> Rituximab Alemtuzumab Trastuzumab	This agents targets CD20, CD52, B-cell antigen which activates apoptosis. Trastuzumab targets against human epidermal growth factor receptor protein-2 (HER-2) and induce the apoptosis in breast cancer.	B-cell lymphoma, Chronic lymphocytic leukaemia, T-cell lymphoma and breast cancer.
	<b>AROMATASE INHIBITORS:</b> Anastrozole Letrozole Exemestane	Aromatase, responsible for conversion of testosterone to estradiol	Estrogen Receptor (ER) positive metastatic breast cancer in post menopausal women that are resistant to tamoxifen therapy.

The MDR1 gene, which encodes P-glycoprotein (P-gp; MDR1, ABCB1) <sup>[10-11]</sup>, a phosphorylated and glycosylated 170-kDa protein of 1,280 amino acids, is the most widely observed mechanism in clinical transport-associated MDR. <sup>[12-13]</sup> Several other ABC transporters have been described: the MDR-associated protein 1 (MRP1, ABCC1), the

mitoxantrone resistance protein (MXR1/BCRP, ABCG2) <sup>[14-15]</sup> and the ABCB4 (MDR3) and ABCB11 (sister P-gp or BSEP) proteins involved in the secretion of hepatic phosphatidyl choline and bile acids, respectively, as well as transport of certain drugs. <sup>[16]</sup> In addition to MRP1, five homologues (MRP2–MRP6) have been cloned and over

expression of MRP2 were shown to confer MDR. [14, 17] MRP3 and MRP5, which are transporters of organic conjugates and nucleosides, respectively, are also implicated in drug resistance. [14] The MRPs ubiquitously expressed in normal tissues and to varying degrees in human cancers belong to the ABCC subfamily comprising 11 genomic regions. Many of these proteins have been identified as ATP-dependent membrane transporters for various drugs and anions, with some such as MRP1 also utilizing glutathione. [18-19]

The most intriguing characteristic distinguishing MDR proteins from other mammalian transporters is their highly promiscuous substrate specificity. [20] In contrast with selective (classical) transport proteins, multidrug transporters, as well as handling unique compounds, translocate a large number of structurally diverse mainly hydrophobic compounds, which explains the cross-resistance to several chemically unrelated compounds, the hallmark of the MDR phenotype. [12-13] Tumors with MDR protein over expression, such as hepatomas, lung or colon carcinomas frequently show intrinsic resistance. P-gp transports large hydrophobic, uncharged or slightly positively charged compounds, while the MRP family is the main transport vehicle for hydrophobic anionic conjugates and extrudes uncharged hydrophobic drugs. Table 2 is a list of commonly used drugs, including important anticancer agents, which are extruded by P-gp.

**Table 2: List of drugs that are extruded by P-glycoprotein.**

<b>Anticancer drugs</b>	<b>Antidiarrhoeal agent</b>
Doxorubicin, Daunorubicin,	Loperamide
Vinblastine, Vincristine, Actinomycin D, Paclitaxel, Teniposide, Etoposide	
<b>HIV protease inhibitors</b>	<b>Anti-gout agent</b>
Amprenavir, Indinavir, Nelfinavir, Ritonavir, Saquinavir	Colchicine
<b>Immunosuppressive drugs</b>	<b>Antibiotic</b>
Cyclosporin A	Erythromycin
<b>Cardiac drugs</b>	<b>Anti-helminthic agent</b>
Digoxin, Quinidine	Ivermectin
<b>Anti-emetic</b>	<b>Anti-tuberculous agent</b>
Ondansetron	Rifampin
<b>Lipid-lowering agent</b>	<b>Fluorescent dye</b>
Lovastatin	Rhodamine-123
<b>Antihistaminic</b>	<b>Dopamine antagonist</b>
Terfenadine	Domperidone
<b>Steroids</b>	
Aldosterone, Hydrocortisone, Cortisol, Corticosterone, Dexamethasone	

The precise physiological function of P-gp in the absence of therapeutics or toxins is probably a protective role. Results of gene knockout experiments in mice support the idea that MDR proteins play a part in protecting the cell from xenobiotics. Tissue distribution of MDR-ABC proteins is quite varied. P-gp is often difficult to detect because of its low level of expression, but it is ubiquitous in those tissues involved in absorption and secretion [12-13] (e.g. epithelial cells of the kidney proximal tubules, superficial columnar epithelial cells of the colon and jejunum, hepatocytes, epithelial cells of pancreatic small ductules, adrenal medulla and cortex) and in a variety of immune cells where it probably contributes significantly to the removal of drugs and toxins from the bone marrow. Its expression varies between individuals and is a function of both genotypic characteristics and of general metabolic/environmental conditions, which may include exposure to heat shock, irradiation, genotoxic stress and inflammatory stimuli as well

as cytokines and growth factors. It has been shown that P-gp-mediated drug transport can be stimulated by the antihypertensive prazosin and by progesterone. [21-22]

The promise of preclinical data on the role of P-gp has been somewhat disappointing in terms of the clinical experience with P-gp modulators to overcome drug resistance. Although P-gp appears to play a very important role in the CNS penetration of drugs, its effect on drug absorption may not be as important as generally believed. In some studies, P-gp has been reported to have prognostic significance in certain types of neoplasms, but very often it has generally failed to show a correlation with clinical response. [23-24] This has led to much controversy regarding the precise role of P-gp in clinically relevant tumor drug resistance. Its precise mode of action also remains a perplexing problem. There have been suggestions that the MDR proteins do not transport drugs *per se* but alter ion transport or signal transduction, which then affects drug distribution. Anticancer drugs and cytotoxic cytokines such as members of the TNF/Fas ligand family play a predominant role in apoptosis induction in tumor cells and are critical in cancer therapy. Given the wide-ranging actions of P-gp, one group has extensively examined its association with cell death. Pathways leading to apoptosis appear to involve a family of cysteine aspartases known as caspases. [25] Using drug-resistant tumor cell lines, their results suggest that P-gp confers resistance to Fas-induced caspase-3 activation and apoptosis. P-gp expressing cells are resistant to a wide range of stimuli that activate the caspase apoptotic cascade, but are not resistant to caspase-independent cell death mediated by pore-forming proteins and GrB (Growth Factor Receptor Bound protein). Inhibition of P-gp with antibody inhibitors completely reverses the resistance to caspase-dependent cell death. [26] They also demonstrated ATP-dependent inhibition of Fas-induced caspase-8 activation but not formation of the death-inducing signal complex. Cullen *et al.* [27], however, found that an MRP-over expressing MDR leukemia subline had the same level of Fas expression as the parental cells and similar apoptotic responses to anti-Fas antibody, questioning the hypothesis that selection of drug resistance results in resistance to Fas-mediated apoptosis.

#### **Genetic Responses**

Drugs such as methotrexate inhibit key enzymes in pathways controlling proliferation. Thus, increased transcription of the gene that encodes the enzyme can lead to increased levels of the target. As the drug concentration will be limited, it will be unable to block the additional enzyme that is being synthesized, and therefore the cell will effectively overcome the inhibitory effect. One manner in which expression can be elevated is through the process of gene amplification, which involves selective replication of a region of the chromosome, resulting in multiple copies of the same gene, with each one being transcribed to produce a high level of mRNA. P-gp activity is also related to the status and level of activity of the MDR1 gene. Rifampicin can induce MDR1 expression. Induction of intestinal P-gp by rifampicin has been shown to be the major mechanism responsible for reduced digoxin levels during concomitant rifampicin therapy; in healthy male volunteers, the oral bio-availability of digoxin decreased by 30% and intestinal P-gp levels were induced 3.5-fold during rifampicin therapy. [28]

Mickley *et al.* [29] found that in several drug-resistant cancer cell lines as well as in DNA from two leukemic patients who

had developed drug resistance, gene rearrangements had occurred resulting in initial activation or increased expression of MDR1. Polymorphism in exon26 (C3435T) of MDR1 is significantly correlated with levels of expression and function of MDR1. Thus, gene amplifications/rearrangements, rifampicin induction and probably other factors can cause MDR1 over expression.

Defects in the apoptotic pathway might constitute an alternative mode of therapy resistance. The p53 protein is an important regulator of the cell cycle and is sensitive to any DNA damage (genotoxic stress) caused during replication, in which case it will normally induce G1 arrest and/or apoptosis to prevent the production of defective cells. Drugs, which increase DNA damage, will therefore lead to p53-mediated cell death. Mutations in this gene are frequently observed in human cancers; loss of p53 function will allow cells with damaged DNA to continue replicating, which means resistance to DNA damaging drugs. From a trial of ovarian carcinoma, Petty *et al.* [30] concluded that enhanced genomic instability due to p53 inactivation might increase the likelihood of development of resistance to CTX over time. In a variety of tumors, p53 deletion was reported to be associated with MDR. [31] Inactivated p53 almost completely suppressed the induction of apoptosis or severely delayed it. Johnson and Fan [32] found that reduced expression of p53 in human breast cancer cells modified response to paclitaxel and 5-FU. It has been suggested that reactivation of mutant p53 may be an effective way of inducing tumor cell death. Susceptibility of tumor cells to programmed cell death is influenced by a series of proto-oncogene and tumor suppressor genes. Other genes, such as h-ras and bcl-2/bax, involved in the apoptotic pathway, have also been implicated in resistance. This type of resistance will affect a wider range (possibly all) of anticancer drugs. It also potentially increases the proportion of surviving mutant cells, which leads to greater tumor heterogeneity.

#### **Enhanced DNA Repair**

Another way that cells can become resistant, for example to cisplatin, is by developing an enhanced ability to remove cisplatin-DNA adducts and to repair cisplatin induced lesions, through the action of DNA repair proteins. Levels of a nuclear protein called XPE-BF (xeroderma pigmentosum group E binding factor) were found to increase early in the development of cisplatin resistance. Excision repair cross-complementing protein (ERCC1) [33], most likely a DNA-binding protein, is another example of a DNA repair protein that may be involved in recognition of cisplatin damage; its expression is elevated in cisplatin-resistant cells compared with that in cells sensitive to cisplatin. The level of ERCC1 has been reported to increase as tumors become resistant to carboplatin. Cross-resistance to carboplatin but not so much to either oxaliplatin or tetraplatin has been observed in cisplatin-resistant cells, so there are opportunities for second-line therapy. Resistance in non-seminomatous germ cell cancer cell lines was 1.7 to 2.2 fold with oxaliplatin compared to 3.9 to 6.1 fold with cisplatin. [34]

#### **Alterations in Target Molecules**

It is possible that during the course of therapy, the target of that therapy could be modified in some way or even decrease to a level where it ceases to have any significant cellular influence and is therefore no longer a useful target to block. A fairly common example of this is encountered with anti-estrogen (e.g. tamoxifen) therapy of breast cancer. Patients

often undergo transition to an endocrine-resistant, from an initially responsive state, in which there is an apparent loss of estrogen receptors in the resistant tumor cells. These patients no longer respond to tamoxifen treatment; however, their tumors can still, temporarily at least, be growth inhibited by inhibitors of estrogen synthesis such as aromatase inhibitors.

[35] This is followed by a state of complete unresponsiveness to any endocrine manipulation. Presumably, the surviving cancer cells are no longer dependent on estrogen for growth and continued attempts to block the now diminished original target, i.e. the estrogen receptor, are fruitless.

Gene mutations are common in cancer cells; indeed it is this phenomenon, which gives that cell its remarkable properties. Cytotoxic drugs are aimed at disabling a component whose continued function is necessary for cell survival; cells that survive the treatment may do so by carrying a gene, for that target, which has mutated in such a way that it produces a protein that retains its activity but no longer binds to the drug, for stereochemical reasons, and is therefore not inhibited by it. The result is a functioning cell resistant to the drug. Resistance to the herbicide, glyphosate, can be induced in plants by transfection with a mutated *aroA* gene which encodes an enzyme necessary for synthesis of aromatic amino acids. The modified enzyme retains its essential catalytic activity but no longer binds glyphosate. Imatinib (Gleevec; STI571) is a tyrosine kinase inhibitor that induces apoptosis by preventing cell growth in cancerous cells by disabling the damaged bcr-abl receptors, preventing ATP binding. In clinical trials treating chronic myeloid leukemia with STI571. Gorre *et al.* [36] found that patients in remission had reactivated bcr-abl activity; 3 of the 11 patients had amplified copies of the oncogenic bcr-abl gene. Two thirds of patients tested harboured a single-point mutation within the ATP-binding site of bcr-abl. Thus, the bcr-abl gene appears important in both the initiation and the maintenance of tumorigenicity. Identifying mutated alleles may help to detect drug-resistant clones prior to clinical relapse.

Topoisomerase, because of its vital role in DNA replication, is a favorite target for CTX. Mutations in this protein, which alter its nuclear localization, render those cells insensitive to drugs such as etoposide designed to block the activity of topoisomerase II. Target molecules may also disappear from cancer cells as a result of the loss of the corresponding gene. Chromosomal losses are a common feature of cancer. Duesberg *et al.* [37] have suggested that it is the aneuploid nature of cancer cells that best explains the development of MDR. They conclude that the cause of this resistance is not simply the loss of drug-sensitive genes when a chromosome is lost, which can happen frequently given the large number of cells undergoing division in a tumor. Chromosome reassortment during mitosis is also capable of activating/inactivating numerous biochemical pathways that could disarm a variety of drugs. By contrast, the chances for a normal cell to lose or gain a chromosome during mitosis are undetectably low under most conditions and hence, it is not usual to see resistance to CTX in normal cells.

Penetration of drugs to their intended site of action is also a problem that is encountered and must be regarded as a form of resistance. The central portion of large tumors tends to have a poor blood supply and drugs will have limited access to this area. Therefore, CTX is more effective for smaller tumors and becomes less so as the tumor becomes larger. Treatment of brain tumors also faces the problems posed by

the blood-brain barrier. This is a dynamic network of vessels, which restrict movement of molecules into the CNS. Many drugs are ineffective because they cannot pass through this barrier. Others, which may initially have been able to penetrate inside, may later be blocked due to the dynamic nature of this resistance. P-gp is an important component of this barrier and is present in high concentration on the apical surface of the endothelial cells.<sup>[38]</sup> While it restricts access of various potentially harmful pharmacologic agents to the brain, it also poses a problem in the treatment of brain diseases. Increasing the concentration of the drug to achieve entry into the brain to circumvent the action of P-gp presents problems of systemic toxicity. Begley<sup>[39]</sup> has reviewed the role of ABC transporters.

Genetic variations in transporter and metabolic enzymes are associated with differences in drug absorption, distribution, metabolism and excretion and are considered to be the major determinants of inter-individual variability. Cytochrome p450s (cyp450) are a group of enzymes that alter the chemical structure of drugs, for elimination. Most drugs that are P-gp substrates are also Cyp3A4 substrates. These enzymes are located in the cells of the intestinal wall, endothelium, liver and other tissues. Genetic differences in cyp450 structure and expression lead to functional differences in drug and nutrient absorption and clearance. Over 50 cyp450 genes are expressed in different tissues of the human body, with more than a thousand identified in all species. CYP3A4 is the most abundantly expressed P450 in human liver and small intestine and is known to metabolize more than 120 different drugs. Hepatic expression of CYP3A4 is known to vary by more than 50-fold among individuals and *in vivo* CYP3A4 enzymatic function (drug clearance) varies by at least 20-fold. The genetic basis for this was reviewed by Lamba *et al.*<sup>[40]</sup> The combination of P-gp and cyp450 largely determines drug absorption and biodistribution to tissues, limiting intestinal transcellular permeability, biliary disposition in hepatocytes, urinary elimination through the renal epithelium and placental transport.

#### **Metabolic Effects**

Xenobiotics often modify high-density apolipoprotein. The result of this is to enhance hepatic drug elimination, reducing its effective plasma concentration. Another physiological response to the presence of drugs is the over expression of drug-metabolizing enzymes or carrier molecules; e.g. the increased production of glutathione<sup>[41]</sup> or ubiquitin contributes to inactivation of the drug by forming conjugates that are excreted. Resistance to cisplatin in ovarian carcinoma cells is associated with increased expression of dihydrodiol dehydrogenase.<sup>[42]</sup> In other cases, *under-expression* of drug-metabolizing enzymes can reduce drug efficacy in situations where an administered inactive prodrug has to undergo catalytic conversion to an active form. Thus, rabinoside is required to be activated by the action of deoxycytidine kinase; loss or mutation of this enzyme will render this drug less effective.

Protein kinase C also plays an important role in both drug exclusion and apoptosis. There are 12 or more different isoforms of this enzyme, which may regulate different cellular phosphorylation events. Drug-resistant breast cancer cells can have elevated activity, but the role of particular isoforms is undetermined. Studies on breast cancer cells have also suggested involvement of the extracellular matrix in

drug resistance.<sup>[43]</sup> It is known that apoptosis can be mediated by activation of the Fas/Fas-L pathway. These authors showed that ligation of b1 integrins by their extracellular matrix ligands inhibits apoptosis mediated by paclitaxel and vincristine, which activate this pathway. These agents act by release of mitochondrial cytochrome c. Integrin mediated protection from the drug-induced apoptosis and inhibition of cytochrome c release were dependent on the activation of the PI 3 kinase/Akt pathway.

#### **Growth Factors**

Serum levels of interleukin (IL)-6 have been found to be elevated in patients with various types of cancer. Conze *et al.*<sup>[44]</sup> demonstrated that autocrine production of IL-6 by breast cancer cells could promote resistance to CTX. Cells sensitive to the CTX did not express appreciable IL-6, whereas high levels were detectable in multidrug-resistant cells. The mechanism of this resistance was attributed to the activation of the CCAAT enhancer binding protein family of transcription factors and induction of MDR1 gene expression. They suggested that as some breast tumors contain IL-6-producing cells this might have potential as a factor for predicting CTX resistance. Song *et al.*<sup>[45]</sup> have shown that chemoresistance may be induced by extracellular factors in tumour-bearing organs. Comparing chemosensitivity and proteins in different tumors and different culture systems, they found elevated levels of acidic and basic fibroblast growth factors in the media of solid and metastatic tumors. These conditioned media induced broad-spectrum resistance to drugs (paclitaxel, doxorubicin and 5-FU) with diverse structures and mechanisms of action. Application in combination, of these two growth factors, could produce a 10-fold increase in drug resistance, whereas suramin, a known inhibitor of fibroblast growth factors, was able to reverse this resistance.

#### **DRUG RESISTANCE TESTING**

Not all patients are necessarily resistant to CTX. Some tumors may be highly resistant to most cytotoxic drugs, while others may be quite sensitive. Therefore, it would be useful to have some tests, which could predict resistance and subsequent clinical failure. This would spare patients from the trauma of ineffective CTX. A company called IMPATH (Los Angeles, Calif., USA) has developed a cell culture drug resistance assay, which they claim can help in the selection of chemotherapeutic agents that have the greatest likelihood of being clinically effective. Their method essentially measures 3H-thymidine uptake into cultured tumour cells, taken from fresh biopsy specimens, in the presence of various drugs; an algorithm applied to the data is used to determine the probability that a patient will respond to the various therapies tested in the assay. Kern and Weisenthal<sup>[46]</sup> reported that this assay used in clinical trials was highly accurate in demonstrating that cells extremely resistant *in vitro* were also resistant *in vivo*. The usefulness of such *in vitro* testing however remains a controversial matter and oncologists still prefer to rely on experience and the results of clinical trials with the drug. There has been much discussion on the subject.

#### **APPROACHES TO OVERCOMING DRUG RESISTANCE**

As the mechanisms responsible for drug resistance become clearer, several strategies for countering this phenomenon are beginning to emerge. The most obvious response, and the one most widely employed, is to use combination drug

therapy. The general rationale for choosing which drugs to combine is to use drugs which are active against the tumour when used individually; to combine drugs that have different modes and sites of action to produce complementary/synergistic rather than just additive effect; to combine drugs with minimally overlapping toxicities, allowing administration of maximally effective doses of each active agent to optimally schedule each drug, and to use drugs with narrowest possible cycle intervals necessary for bone marrow recovery. Drugs that are typically used in combination therapy for breast cancer are listed in Table 3. High-dose CTX can destroy the tumour cells before they have the opportunity to form resistant colonies, but this often comes at too great a cost to the patient. Less severe strategies are needed. As the action of the ABC transporters is thought the most significant reason for resistance, they have received the most attention.

**Table 3: Chemotherapy drug combination used for breast cancer treatment.**

<b>CMF</b>	Cyclophosphamide, methotrexate, 5-FU
<b>AC</b>	Doxorubicin, cyclophosphamide
<b>CAF</b>	Cyclophosphamide, doxorubicin, 5-FU
<b>ACT</b>	Doxorubicin, cyclophosphamide, paclitaxel
<b>CEF</b>	Cyclophosphamide, epirubicin, 5-FU
<b>CMFVP</b>	Cyclophosphamide, methotrexate, 5-FU, vincristine, prednisone
<b>ACTa</b>	Doxorubicin, cyclophosphamide, Taxotere
<b>AT</b>	Doxorubicin, Taxotere (docetaxel)

**Table 4: List of drugs antagonized the P-gp.**

<b>Immunosuppressant</b>	Cyclosporin A, Valspodar
<b>HIV protease inhibitors</b>	Ritonavir, Saquinavir, Nelfinavir
<b>Anti-arrhythmic agent</b>	Quinidine
<b>Calcium channel blocker</b>	Verapamil
<b>Antifungal agent</b>	Ketoconazole
<b>Sedative</b>	Midazolam
<b>Peptide chemosensitizer</b>	Reversin 121, Reversin 205
<b>Acridone carboxamide</b>	GG918 (GF120918)
<b>Progesterone antagonist</b>	Mifepristone
<b>Anti-oestrogen</b>	Tamoxifen

A large number of drugs have been identified that are pharmacological antagonists of particularly the P-gp. These include a variety of quite distinct groups of compounds, some of which are listed in Table 4. Used in conjunction with the cytotoxic drugs already mentioned, these can potentiate their effects by allowing those drugs to remain in the target cells longer. These agents may be more properly regarded as modulators or reversing agents as even those that appear to be inhibitors of drug efflux may themselves be substrates, in so far as they can stimulate ATPase activity. The use of these in combination can subvert the cell's defense. For example, P-gp blocks absorption in the gut and may be considered part of the 'first pass effect'; it can act as a 'gatekeeper' for subsequent P450 cytochrome action. If one drug is a substrate of both P-gp and the cytochrome P450 subfamily IIIA (nifedipine oxidase) polypeptide 4 (CYP3A4; found in close proximity in the intestinal mucosa), and a second drug is added that is a modulator (e.g. erythromycin, mibefradil, ketoconazole), then the first drug will be allowed to increase its intracellular accumulation as a result of inhibition of the P-gp blockade. Since CYP3A4 is also inhibited, unmetabolised drug will enter the circulation.

Another example is the entry of the antidiarrhoeal, loperamide, into the CNS (from which it is normally excluded) by the simultaneous administration of the P-gp modulator, quinidine.<sup>[47]</sup> The use of P-gp inhibitors may lead

to undesirable consequences. Thus, the simultaneous use of cytotoxic drugs and agents that block P-gp function has raised questions of safety. In knockout mice with a genetic disruption of the MDR1a P-gp, much higher levels of substrate drugs accumulated in the brain, with markedly slower elimination from the circulation, resulting in dramatically increased toxicity to normal tissue. Another mode of MDR reversal utilizes monoclonal antibodies, several of which inhibit P-gp-mediated drug efflux *in vitro*. For *in-vivo* applications, companies such as Immunomedics Inc. are developing polyspecific antibodies targeting both MDR protein and cancer epitopes. These antibodies may also be conjugated to cytotoxins, which can be internalized.<sup>[48]</sup>

More recent innovations to inhibit MDR proteins include transcriptional/translational inhibition through the introduction of antisense oligonucleotides or ribozymes.<sup>[49]</sup> Interference<sup>[50]</sup> is another approach to knock out specific mRNAs and is rapidly gaining popularity; MDR genes would represent a good target. However, as many of these methods require gene targeting and transfer, they are unlikely to produce any really significant *in-vivo* applications anytime soon, despite considerable progress in the general approach using animal models. A more immediate strategy, termed 'metronomic dosing', is to simultaneously target the associated endothelial cells<sup>[51]</sup>, which support tumour cell growth. This involves combining anti-angiogenic drugs with a more frequent regimen of cytotoxic agents; endothelial cells are more susceptible to CTX and a lower dose of CTX agents can be used, resulting in reduced side-effects. Experiments in tumour-bearing mice have shown that administration of DC101, a blocker of vascular endothelial growth factor, and a submaximal tolerated dose of vinblastine induced effective tumour regression. Given individually, both agents were ineffective.<sup>[52]</sup>

Targeting of growth factor receptors, which are over expressed in breast cancer, with antibodies has been successfully employed for reducing tumour burden. The prime example of this is the use of trastuzumab aimed against the HER2 protein. Cetuximab is another antibody that specifically blocks the epidermal growth factor receptor (EGFR), which is over expressed in several cancers, particularly of the GI tract.<sup>[53]</sup> It has been successfully used in patients who were refractory to treatment with fluorouracil and irinotecan. The effectiveness of the combination of irinotecan and cetuximab in patients with irinotecan-refractory tumors suggests that cetuximab may circumvent irinotecan resistance.<sup>[54]</sup> It is suggested that in this case bevacizumab may improve delivery of CTX by altering tumour vasculature and decreasing the elevated interstitial pressure in tumors.<sup>[55]</sup>

#### PUTTING RESISTANCE TO GOOD USE

One of the major problems with CTX is its unwanted toxicity on bone marrow. Although this tissue recovers after cessation of treatment, the patient is severely immune compromised and has to be given additional protective treatment. The phenomenon of drug resistance could be turned to advantage for the patient's benefit. Stem cells taken from the patient could be transduced with a retroviral construct containing an MDR gene and used to repopulate the bone marrow, conferring resistance against subsequent exposure to CTX.<sup>[56]</sup> Knockout experiments in mice have demonstrated targeted disruption of the MDR1b gene.<sup>[57]</sup> Several clinical trials are examining the possibility of



delivering MDR1 gene-expressing vectors into cancer patients to induce chemoprotection or for *in vivo* selection of regenerating stem cells. Preliminary results seem to indicate that only modest levels of protection can be achieved *in-vivo*, due to the very low percentages of patients' cells expressing MDR1 following hematopoietic reconstitution.<sup>[58]</sup> The old adage that prevention is better than cure applies as much to this situation. A concerted effort should be made to identify factors that can predict the onset of resistance before its clinical manifestation. This could allow the physician valuable lead time to alter either the combination of cytotoxic drugs or the form of the therapy. Attempts to devise methods of early detection of metastatic relapse have concentrated mainly on the development of very sensitive molecular assays for the detection of tumour-associated genes/proteins in circulating cells in the blood or micrometastases in the bone marrow.<sup>[59-61]</sup> The continual monitoring of cancer patients on therapy, for the traditional tumour markers such as carcino-embryonic antigen, has proved of limited use except in a few cancers; e.g. bHCG is a good indicator of early relapse in choriocarcinomas. The absence of a clearly defined molecule that is produced or is present only in cancer cells has greatly hindered these efforts. For the common adenocarcinomas, epithelial cell markers have been investigated on the premise that such cells are normally absent from blood, and if they appear in cancer patients, they must originate from a growing tumour. Without this early warning system, the problem of overcoming development of chemoresistance is quite considerable. In an ideal situation, therapy would be tailored to suit the individual at the outset; this is unlikely at least for the very near future, despite rapid progress in pharmacogenomics. In the meantime, a better understanding of the mechanisms of resistance will at least allow the physician to modulate the therapy on a need to do basis.

## REFERENCES

- Roskoski R, Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. *Biochem Biophys Res Commun* 2004; 319: 1-11.
- Gross ME, Shazer RL, Agus DB. Targeting the HER-kinase axis in cancer. *Semin Oncol* 2004; 31: 9-20.
- Gruner BA, Weitman SD. The folate receptor as a potential therapeutic anticancer target. *Invest New Drugs* 1999; 16: 205-219.
- Reddy JA, Low PS. Folate-mediated targeting of therapeutic and imaging agents to cancers. *Crit Rev Ther Drug Carrier Syst* 1998; 15: 587-627.
- Dendreon Corporation (US). Immunotherapy for asymptomatic metastatic androgen independent prostate cancer, 2010.
- IARC monographs on the evaluation of carcinogenic risks to humans, volume 90, human papillomaviruses. Lyon: International Agency for Research on Cancer; 2006.
- Sharma HL, Sharma KK. editors. Principles of pharmacology. Hyderabad: Paras Medical Publisher; 2009.
- Hurley LH. DNA and its associated processes as targets for cancer therapy. *Nat Rev Cancer* 2002; 2: 188-200.
- Kast C, Gros P. Topology mapping of the amino terminal half of multidrug resistance associated protein by epitope insertion and immunofluorescence. *J Biol Chem* 1997; 272: 26479-26487.
- Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. *Biochem Biophys Acta* 1976; 455: 152-162.
- Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, *et al.* Internal duplication and homology with bacterial transport proteins in the MDR1 (P-glycoprotein) gene from multidrug-resistant human cells. *Cell* 1986; 47: 381-389.
- Endicott JA, Ling V. The biochemistry of P-glycoprotein mediated multidrug resistance. *Ann Rev Biochem* 1989; 58: 137-171.
- Higgins CF. ABC transporters: From microorganisms to man. *Annu Rev Cell Biol* 1992; 8: 67-113.
- Cole SP, Deeley RG. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. *Bioessays* 1998; 20: 931-940.
- Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: New understanding of multidrug resistance systems, their properties and clinical significance. *Cell Mol Life Sci* 2001; 58: 931-959.
- Smith AJ, van Helvoort A, van Meer G, Szabo K, Welker E, Szakacs G, *et al.* MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. *J Biol Chem* 2000; 275: 23530-23539.
- Kool M, van der Inden M, de Haas M, Baas F, Borst P. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. *Cancer Res* 1997; 57: 3537-3547.
- Homolya L, Varadi A, Sarkadi B. Multidrug resistance-associated proteins: Export pumps for conjugates with glutathione, glucuronate or sulfate. *Biofactors* 2003; 17: 103-114.
- Haimeur A, Conseil G, Deeley RG, Cole SP. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: Biology, substrate specificity and regulation. *Curr Drug Metab* 2004; 5: 21-53.
- Zaman GJ, Lankelma J, van Tellingen O, Beijnen J, Dekker H, Paulusma C, *et al.* Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. *Proc Natl Acad Sci USA* 1995; 92: 7690-7694.
- Schinkel AH. The physiological function of drug-transporting P-glycoproteins. *Semin Cancer Biol* 1997; 8: 161-170.
- Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. *Proc Natl Acad Sci USA* 1987; 84: 7735-7738.
- Consoli U, Santonocito A, Stagno F, Fiumara P, Privitera A, Parisi G, *et al.* Multidrug resistance mechanisms in chronic lymphocytic leukaemia. *Br J Haematol* 2002; 116: 774-780.
- Kumta SM, Zhu QS, Lee KM, Griffith J, Chow LT, Leung PC. Clinical significance of P-glycoprotein immunohistochemistry and doxorubicin binding assay in patients with osteosarcoma. *Int Orthop* 2001; 25: 279-282.
- Henkart PA. ICE family proteases: Mediators of all apoptotic cell death? *Immunity* 1996; 4: 195-201.
- Johnstone RW, Cretnay E, Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. *Blood* 1999; 93: 1075-1085.
- Cullen KV, Davey RA, Davey MW. Drug resistance does not correlate with resistance to Fas-mediated apoptosis. *Leuk Res* 2001; 25: 69-75.
- Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, *et al.* The effect of rifampin treatment on intestinal expression of human MRP transporters. *Am J Pathol* 2000; 157: 1575-1580.
- Mickley LA, Spengler BA, Knutsen TA, Biedler JL, Fojo T. Gene rearrangement: A novel mechanism for MDR-1 gene activation. *J Clin Invest* 1997; 99: 1947-1957.
- Petty R, Evans A, Duncan I, Kurbacher C and Cree I. Drug resistance in ovarian cancer-The role of p53. *Pathol Oncol Res* 1998; 4: 97-102.
- Grunicke H. Oncogenes and drug resistance. *Deutsche Krebsgesellschaft.V. Materials*, 23rd Congr, Berlin, June 8-12, 1998.
- Johnson KR, Fan W. Reduced expression of p53 and p21WAF1/CIP1 sensitizes human breast cancer cells to paclitaxel and its combination with 5-fluorouracil. *Anticancer Res* 2002; 22: 3197-3204.
- Rosell R, Taron M, Ariza A, Barnadas A, Mate JL, Reguart N, *et al.* Molecular predictors of response to chemotherapy in lung cancer. *Semin Oncol* 2004; 31: 20-27.
- Dunn TA, Schmoll HJ, Grunwald V, Bokemeyer C, Casper J. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. *Invest New Drugs* 1997; 15: 109-114.
- Campos SM. Aromatase inhibitors for breast cancer in postmenopausal women. *Oncologist* 2004; 9: 126-136.
- Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, *et al.* Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. *Science* 2001; 293: 876-880.
- Duesberg P, Stindl R, Hehlmann R. Origin of multidrug resistance in cells with and without multidrug resistance genes: Chromosome reassortments catalyzed by aneuploidy. *Proc Natl Acad Sci USA* 2001; 98: 11283-11288.



38. Ramakrishnan P. The role of P-glycoprotein in the blood-brain barrier. *Einstein Q J Biol Med* 2003; 19: 160-165.
39. Begley DJ. ABC transporters and the blood brain barrier. *Curr Pharm Des* 2004; 10: 1295- 1312.
40. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. *Adv Drug Deliv Rev* 2002; 54: 1271-1294.
41. Gamesik MP, Dubay GR, Cox BR. Increased rate of glutathione synthesis from cystine in drug-resistant MCF-7 cells. *Biochem Pharmacol* 2002; 63: 843-851.
42. Deng HB, Parekh HK, Chow KC, Simpkins H. Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells. *J Biol Chem* 2002; 277: 15035-15043.
43. Aoudjit F, Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. *Oncogene* 2001; 20: 4995-5004.
44. Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, Johnson P, *et al.* Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. *Cancer Res* 2001; 61: 8851-8858.
45. Song S, Wientjes MG, Gan Y, Au JL. Fibroblast growth factors: An epigenetic mechanism of broad spectrum resistance to anticancer drugs. *Proc Natl Acad Sci USA* 2000; 97: 8658- 8663.
46. Kern DH, Weisenthal LM. Highly specific prediction of anti-neoplastic drug resistance with an in-vitro assay using suprapharmacologic drug exposures. *J Natl Cancer Inst* 1990; 82: 582-588.
47. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. Increased drug delivery to the brain by P-glycoprotein inhibition. *Clin Pharmacol Ther* 2000; 68: 231-237.
48. Pearson JW, Fogler WE, Volker K, Usui N, Goldenberg SK. Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody. *J Natl Cancer Inst* 1991; 83: 1386-1391.
49. Pawlak W, Zolnieriek J, Sarosiek T, Szczylik C. Antisense therapy in cancer. *Cancer Treat Rev* 2000; 26: 333-350.
50. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature* 2000; 411: 494-498.
51. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. *Bioessays* 1991; 13: 31-36.
52. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, *et al.* Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. *J Clin Invest* 2000; 105: R15-R24.
53. Porebska I, Harlozinska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. *Tumour Biol* 2000; 21: 105-115.
54. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, *et al.* Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med* 2004; 351: 337-345.
55. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. *Nat Med* 2001; 7: 987-989.
56. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. *Annu Rev Pharmacol Toxicol* 1999; 39: 361-398.
57. Altuvia S, Stein WD, Goldenberg S, Kane SE, Pastan I, Gottesman MM. Targeted disruption of the mouse *mdr1b* gene reveals that steroid hormones enhance MDR gene expression. *J Biol Chem* 1993; 268: 27127-27132.
58. Sorrentino BP. Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. *Nat Rev Cancer* 2002; 2: 431-441.
59. Schoenfield A, Luqmani YA, Sinnett HD, Shousha S, Coombes RC. Keratin 19 mRNA measurement to detect micrometastases in lymph nodes in breast cancer patients. *Br J Cancer* 1996; 74: 1639-1642.
60. Pantel K, von Knebel Doeberitz M. Detection and clinical relevance of micrometastatic cancer cells. *Curr Opin Oncol* 2000; 12: 95-101.
61. Zehentner BK. Detection of disseminated tumor cells: Strategies and diagnostic implications. *Expert Rev Mol Diagn* 2002; 2: 41-48.